FI91150B - Förfarande för framställning av nya terapeutiskt användbara 4,5,6-substituerade N-(substituerad-fenyl)-2-pyrimidinaminer - Google Patents

Förfarande för framställning av nya terapeutiskt användbara 4,5,6-substituerade N-(substituerad-fenyl)-2-pyrimidinaminer Download PDF

Info

Publication number
FI91150B
FI91150B FI870113A FI870113A FI91150B FI 91150 B FI91150 B FI 91150B FI 870113 A FI870113 A FI 870113A FI 870113 A FI870113 A FI 870113A FI 91150 B FI91150 B FI 91150B
Authority
FI
Finland
Prior art keywords
pyridinyl
phenyl
methyl
pyrimidinamine
alkyl
Prior art date
Application number
FI870113A
Other languages
English (en)
Finnish (fi)
Other versions
FI870113A (sv
FI91150C (sv
FI870113A0 (sv
Inventor
Lawrence Wayne Torley
Bernard D Johnson
John Paul Dusza
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25224278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI91150(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI870113A0 publication Critical patent/FI870113A0/sv
Publication of FI870113A publication Critical patent/FI870113A/sv
Publication of FI91150B publication Critical patent/FI91150B/sv
Application granted granted Critical
Publication of FI91150C publication Critical patent/FI91150C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Dental Preparations (AREA)

Claims (9)

1. Förfarande för framställning av nya terapeu-tiskt användbara 4,5,6-substituerade N-(substituerad-fe-5 nyl)-2-pyrimidinaminer med formeln I och deras farmakolo-giskt godtagbara syraadditionssalter f1 /K ^ 1 -R2
10 R4“^4/3N (I) R3 i vilken formel R3 är väte, alkyl(Cj-C3) eller N,N-dime-15 tylaminoetyl; R2 är mono- eller polysubstituerad fenyl, väri substituenterna är alkyl (Ci-Cs), alkoxi(C3-C3), klor, brom, jodi, trifluonnetyl, hydroxi, fenyl, amino, monoalkyl(C1-C3)amino, dialkyl(C1-C3)amino, alkyl(Cj-Cj)keto, propenyloxi, karboxyl, oxiättiksyra, oxiättiksyra-20 etylester, sulfonamido, NjN-dialkylCC^-CaJsulfonamido, N- metylpiperazinyl, piperidinyl, lH-imidazol-l-yl, eller g-rupper, vars formler är O 0 R
25 -CO-R, -NH-C-R, -NR-C-R, -0-(CH_) -NC^_ 1. n A R NHCHO N-OH N-OCH-, n / I II H 3 -C-NH-(CH2)n-N , -CH-CHj, -C-CH3, -C-CH3 30 Γ2 ° /-\ -CH-CH-, -NHCH--C-N <. , -N N ~V 3 2 \_/ R6 -(CH_)m-R.,, -X-(CH„)m-R, ja S / \ 27 1 ' -X-CH--C-N' N-Rp 35 2 \_/ 8 II 91150 111 väri R är alkyl(C1-C3), X är syre (-0-) eller svavel (-S-), m är 1 - 3, n är 2 eller 3, R6 är väte, alkyl-(Ci-Cj), alkoxiiCj-Ca), klor, brom, jodi eller trifluor-metyl, R7 är lH-iraidazol-l-yl eller morfolino ja R8 är 5 alkyl(Ci-Ca), fenyl eller monosubstituerad fenyl, vari substituenterna är alkyl(C^Ca), halogen eller trifluor-metyl; R3 är 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-metyl-3-pyridinyl, 6-metyl-3-pyridinyl, 2-furanyl, 5-me-tyl-2-furanyl, 2,5-dimetyl-3-furanyl, 2-tienyl, 3-tienyl, 10 5-metyl-2-tienyl, 2-fenotiazinyl, 2-pyrazinyl, 2-bensofu-ranyl, 2-(pyridin-N-oxid), 3-(pyridin-N-oxid), 4-(pyridi-n-N-oxid), lH-indol-2-yl, lH-indol-3-yl, 1-metyl-lH-pyr-rol-2-yl, 4-kinolyl, 4-pyridinyl-metyljodidi; R4 är väte eller alkyl(C^-Ca); och R5 är väte eller alkyl-15 (Ci-Ca), kännetecknat därav, att ett alka-noylheteroarylderivat med formeln 0 « R3-C-CH2-R4 20 vari R3 och R4 är definierade ovan, kondenseras med N,N-di(lägrealkyl)formamid eller acetamid(lägrealky1)acetal vid 50 - 150 °C:ssa under 2-24 timmar, varvid 3-di(lägrealkyl )aminoakrylf enon erhälles, vars formel är 25 ? ** Ψ R3-C-CÄ c-N(lägrealkyl)2 som sedan cykliseras med en substituerad fenylguanidin 30 med formeln HN ^R. / V h2n ^r2 35 112 R: och R2 är definierade ovan, i ett neutralt organiskt lösningsmedel vid koktemperatur under 6-48 timmar.
2. Förfarande enligt patentkrav 1, känne-t e c k n a t därav, att man framställer 5 N-[3-(ΙΗ-imidazol-l-yl)fenyl]-4-(4-pyridinyl)-2-pyrimi- dinamin, N-[3-(1H-imidazol-1-y1)fenyl]-4-(2-pyridinyl)-2-pyrimi-dinamin, N,N-dimetyl-N'-[4-metyl-6-(4-pyridinyl)-2-pyrimidinyl]-10 1,4-bensendiamin, Ν' -[4-(2-furanyl)-5-metyl-2-pyrimidinyl]-N,N-dimetyl-l, 4-bensendiamin, N-[4-(dimetylamino)fenyl]-4-(4-pyridinyl)-2-pyrimidin-amin, 15 4-(2-furanyl)-N-(3-metylfenyl)-2-pyrimidinamin, N-[4-[2-(dietylamino)etoxi]fenyl]-4-(4-pyridinyl)-2-pyri-midinamin, N-(4-etylfenyl)-4-(4-pyridinyl)-2-pyrimidinamin, N,N-dimetyl-N'-[4-(3-pyridinyl)-2-pyrimidinyl]-1,4-ben-20 sendiamin, trihydrokloridi, N-[4-( lH-imidazol-l-yl)fenyl]-4-(3-pyridinyl)-2-pyrimidinamin, N-[4-(4-metyl-l-piperazinyl)fenyl]-4-(3-pyridinyl)-2-pyrimidinamin,
25 N-(3-metylfenyl)-4-(4-pyridinyl)-2-pyrimidinamin, N-(4-etylfenyl)-4-(6-metyl-3-pyridinyl)-2-pyrimidinamin, N-(4-etylfenyl)-6-metyl-4-(6-metyl-3-pyridinyl)-2-pyrimidinamin, N-(4-etylfenyl)-4-(2-pyrazinyl)-2-pyrimidinamin,
30 N-( 3-metylfenyl)-4-(2-pyrazinyl)-3-pyrimidinamin, N,N-dimetyl-N'-[4-(3-metyl-2-tienyl)-2-pyrimidinyl]-1,4-bensendiamin eller N-(3-metoxifenyl)-4-(3-metyl-2-tienyl)-2-pyrimidinamin. I!
FI870113A 1986-01-13 1987-01-13 Förfarande för framställning av nya terapeutiskt användbara 4,5,6-substituerade N-(substituerad-fenyl)-2-pyrimidinaminer FI91150C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81795186A 1986-01-13 1986-01-13
US81795186 1986-01-13

Publications (4)

Publication Number Publication Date
FI870113A0 FI870113A0 (sv) 1987-01-13
FI870113A FI870113A (sv) 1987-07-14
FI91150B true FI91150B (sv) 1994-02-15
FI91150C FI91150C (sv) 1994-05-25

Family

ID=25224278

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870113A FI91150C (sv) 1986-01-13 1987-01-13 Förfarande för framställning av nya terapeutiskt användbara 4,5,6-substituerade N-(substituerad-fenyl)-2-pyrimidinaminer

Country Status (18)

Country Link
EP (1) EP0233461B2 (sv)
JP (1) JPH0780857B2 (sv)
KR (1) KR900004693B1 (sv)
AT (1) ATE135699T1 (sv)
AU (2) AU591223B2 (sv)
BR (1) BR1100989A (sv)
CA (1) CA1320201C (sv)
DE (1) DE3751742T3 (sv)
DK (1) DK171251B1 (sv)
ES (1) ES2087056T3 (sv)
FI (1) FI91150C (sv)
GR (1) GR3019455T3 (sv)
HU (1) HU198708B (sv)
IE (1) IE74202B1 (sv)
NZ (1) NZ218924A (sv)
PH (1) PH25056A (sv)
SG (1) SG47583A1 (sv)
ZA (1) ZA87219B (sv)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
FR2632521B1 (fr) * 1988-06-10 1990-09-14 Rhone Poulenc Sante Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent
IE62023B1 (en) * 1989-01-02 1994-12-14 Boots Co Plc Therapeutic agents
GB8903592D0 (en) * 1989-02-16 1989-04-05 Boots Co Plc Therapeutic agents
IN172842B (sv) * 1990-05-17 1993-12-11 Boots Pharmaceuticals Limited
CN1037346C (zh) * 1990-06-29 1998-02-11 布茨公司 降血糖的脒类和胍类的制备方法
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
US5162328A (en) * 1991-12-31 1992-11-10 American Cyanamid Company N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine and pharmacologically acceptable salts
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
US5196431A (en) * 1992-02-24 1993-03-23 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (sv) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5612340A (en) * 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
ES2262137T3 (es) * 1993-10-01 2006-11-16 Novartis Ag Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
ATE208772T1 (de) * 1993-10-01 2001-11-15 Novartis Erfind Verwalt Gmbh Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
WO1997033883A1 (en) 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
CA2401748A1 (en) * 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7078410B2 (en) 2001-02-20 2006-07-18 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of GSK3-related disorders
GB0107901D0 (en) 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
MXPA04002914A (es) 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
KR20040062557A (ko) * 2001-11-01 2004-07-07 얀센 파마슈티카 엔.브이. 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체
EP1448556A1 (en) 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
AR038368A1 (es) 2002-02-01 2005-01-12 Novartis Ag Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2006021803A2 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
ES2397362T3 (es) 2004-12-17 2013-03-06 Amgen Inc. Compuestos de aminopirimidina como inhibidores de PLK
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
JP2009519218A (ja) 2005-11-03 2009-05-14 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピリミジニル−チオフェンキナーゼモジュレータ
US20100048597A1 (en) * 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
PT2200436E (pt) 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
BRPI0906799A2 (pt) 2008-01-11 2015-07-14 Hoffmann La Roche Moduladores para amiloide beta
CA2713716A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
EP2355817A1 (en) 2008-11-10 2011-08-17 F. Hoffmann-La Roche AG Heterocyclic gamma secretase modulators
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
RU2486180C1 (ru) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Способ получения 2-ариламино-4-гетарилпиримидинов
WO2014055972A2 (en) * 2012-10-05 2014-04-10 The Regents Of The University Of California A new chemical entity useful for treating various diseases
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2，4-二取代嘧啶衍生物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB735702A (en) * 1952-03-18 1955-08-24 Wellcome Found Improvements in and relating to 2,4-diaminopyrimidines and methods of making the same
US4512993A (en) * 1983-07-25 1985-04-23 Sterling Drug Inc. 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof
US4504482A (en) * 1983-07-28 1985-03-12 Sterling Drug Inc. [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof
GB8412184D0 (en) * 1984-05-12 1984-06-20 Fisons Plc Biologically active nitrogen heterocycles
EP0164204A1 (en) † 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
US4725600A (en) † 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
JPS62501632A (ja) * 1985-02-05 1987-07-02 ジ・アップジョン・カンパニ− ４−置換−６−アリ−ルピリミジン化合物
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines

Also Published As

Publication number Publication date
IE870074L (en) 1987-07-13
DK15187A (da) 1987-07-14
GR3019455T3 (en) 1996-06-30
PH25056A (en) 1991-01-28
AU6751887A (en) 1987-07-16
ZA87219B (en) 1987-08-26
JPH0780857B2 (ja) 1995-08-30
KR900004693B1 (ko) 1990-07-02
AU5057890A (en) 1990-07-26
IE74202B1 (en) 1997-07-16
FI870113A (sv) 1987-07-14
DE3751742T3 (de) 2002-11-21
CA1320201C (en) 1993-07-13
EP0233461B2 (en) 2002-05-29
DE3751742T2 (de) 1996-11-21
EP0233461B1 (en) 1996-03-20
ATE135699T1 (de) 1996-04-15
JPS62223177A (ja) 1987-10-01
FI91150C (sv) 1994-05-25
DK15187D0 (da) 1987-01-13
DK171251B1 (da) 1996-08-12
AU621461B2 (en) 1992-03-12
ES2087056T3 (es) 1996-07-16
NZ218924A (en) 1990-04-26
FI870113A0 (sv) 1987-01-13
EP0233461A3 (en) 1988-05-25
EP0233461A2 (en) 1987-08-26
HU198708B (en) 1989-11-28
AU591223B2 (en) 1989-11-30
KR870007154A (ko) 1987-08-17
BR1100989A (pt) 1999-11-09
SG47583A1 (en) 1998-04-17
HUT43582A (en) 1987-11-30
DE3751742D1 (de) 1996-04-25

Similar Documents

Publication Publication Date Title
FI91150B (sv) Förfarande för framställning av nya terapeutiskt användbara 4,5,6-substituerade N-(substituerad-fenyl)-2-pyrimidinaminer
JP5818901B2 (ja) 疼痛、精神病性障害、認知障害、またはアルツハイマー病の治療のためのアルファ‐７ニコチン性受容体修飾薬
EP2114955B1 (en) Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP6035259B2 (ja) Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
US7879856B2 (en) Diaminothiazoles useful as Axl inhibitors
JP4782344B2 (ja) ベンザゾール誘導体と、そのｊｎｋモジュレータとしての利用法
EP3189043B1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
US20120088768A1 (en) Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
US20130281428A1 (en) Pyridone Derivatives
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
BG64098B1 (bg) Заместени аза- и диазациклохептанови и циклооктанови производни и използването им
CN100558718C (zh) 哌嗪基和二氮杂环庚基苯甲酰胺和硫代苯甲酰胺
WO2008089034A2 (en) Cytokine inhibitors
BG63487B1 (bg) Използване на хетероциклени съединения
WO2004039795A2 (en) Amide compounds for the treatment of hyperlipidemia
WO1997043278A1 (en) Somatostatin agonists and antagonists
CN102112450A (zh) 5-炔基-嘧啶
CN112313224A (zh) Atf6抑制剂和其用途
CN106132950A (zh) 化合物和使用方法
JP2007538068A (ja) 新規な縮合複素環およびそれらの使用
CA3134510A1 (en) Compounds and uses thereof
ES2351393T3 (es) Sulfopirroles.
EP3356363A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
EP1294699A2 (en) Modulators of tnf- alpha signalling
JP2857693B2 (ja) 新規なピリジル‐およびピリミジル誘導体

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: AMERICAN CYANAMID COMPANY